Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles
Yuxin Zhong,1 Jing Zhang,2 Xiaofeng Bai,1 Yuemin Sun,1 Hao Liu,1 Shuai Ma,1 Yang Li,1 Wenzhe Kang,1 Fuhai Ma,1 Weikun Li,1 Yantao Tian1 1Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-06-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/lobaplatin-in-prophylactic-hyperthermic-intraperitoneal-chemotherapy-f-peer-reviewed-article-CMAR |
| _version_ | 1819145168846061568 |
|---|---|
| author | Zhong Y Zhang J Bai X Sun Y Liu H Ma S Li Y Kang W Ma F Li W Tian Y |
| author_facet | Zhong Y Zhang J Bai X Sun Y Liu H Ma S Li Y Kang W Ma F Li W Tian Y |
| author_sort | Zhong Y |
| collection | DOAJ |
| description | Yuxin Zhong,1 Jing Zhang,2 Xiaofeng Bai,1 Yuemin Sun,1 Hao Liu,1 Shuai Ma,1 Yang Li,1 Wenzhe Kang,1 Fuhai Ma,1 Weikun Li,1 Yantao Tian1 1Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of China; 2Department of Abdominal Surgery, Huanxing Cancer Hospital, Chaoyang District, Beijing 100122, People’s Republic of ChinaCorrespondence: Yantao Tian Email tianyantao@cicams.ac.cnObjective: This study aims to evaluate the safety and efficacy of lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer.Methods: Advanced gastric cancer patients who underwent radical gastric resection and/or prophylactic HIPEC were systematically reviewed in our department from January 2016 to June 2017. All enrolled patients were grouped in either HIPEC or non-HIPEC groups. Clinical data were collected and analyzed.Results: A total of 129 patients were enrolled with 61 cases in the HIPEC group and 68 in the non-HIPEC group. The two groups were well balanced in terms of clinical characteristics. In patients of the HIPEC group, three suffered leakage from the duodenal stump or anastomosis, one suffered abnormal bleeding and two were found to have abnormal routine blood tests; no significant difference in adverse events between groups, however, was noted (p > 0.05) and most patients recovered uneventfully. During follow-up, peritoneal recurrence was significantly less among HIPEC patients (p = 0.029), with only three suffering peritoneal recurrence, as compared to 12 non-HIPEC patients. In addition, the estimated illness-specific 3-year disease-free survival rate was significantly higher in the HIPEC group as compared to the non-HIPEC group (89.4% vs.73.9%; p = 0.031).Conclusion: Lobaplatin in prophylactic HIPEC is safe for advanced gastric cancer patients after treatment by radical resection and can effectively improve illness-specific 3-year disease-free survival.Keywords: gastric cancer, hyperthermic intraperitoneal chemotherapy, lobaplatin, safety |
| first_indexed | 2024-12-22T12:53:45Z |
| format | Article |
| id | doaj.art-06632973b73c47f7a3db5ab49c6b0e6f |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-22T12:53:45Z |
| publishDate | 2020-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-06632973b73c47f7a3db5ab49c6b0e6f2022-12-21T18:25:10ZengDove Medical PressCancer Management and Research1179-13222020-06-01Volume 125141514654891Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy ProfilesZhong YZhang JBai XSun YLiu HMa SLi YKang WMa FLi WTian YYuxin Zhong,1 Jing Zhang,2 Xiaofeng Bai,1 Yuemin Sun,1 Hao Liu,1 Shuai Ma,1 Yang Li,1 Wenzhe Kang,1 Fuhai Ma,1 Weikun Li,1 Yantao Tian1 1Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of China; 2Department of Abdominal Surgery, Huanxing Cancer Hospital, Chaoyang District, Beijing 100122, People’s Republic of ChinaCorrespondence: Yantao Tian Email tianyantao@cicams.ac.cnObjective: This study aims to evaluate the safety and efficacy of lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer.Methods: Advanced gastric cancer patients who underwent radical gastric resection and/or prophylactic HIPEC were systematically reviewed in our department from January 2016 to June 2017. All enrolled patients were grouped in either HIPEC or non-HIPEC groups. Clinical data were collected and analyzed.Results: A total of 129 patients were enrolled with 61 cases in the HIPEC group and 68 in the non-HIPEC group. The two groups were well balanced in terms of clinical characteristics. In patients of the HIPEC group, three suffered leakage from the duodenal stump or anastomosis, one suffered abnormal bleeding and two were found to have abnormal routine blood tests; no significant difference in adverse events between groups, however, was noted (p > 0.05) and most patients recovered uneventfully. During follow-up, peritoneal recurrence was significantly less among HIPEC patients (p = 0.029), with only three suffering peritoneal recurrence, as compared to 12 non-HIPEC patients. In addition, the estimated illness-specific 3-year disease-free survival rate was significantly higher in the HIPEC group as compared to the non-HIPEC group (89.4% vs.73.9%; p = 0.031).Conclusion: Lobaplatin in prophylactic HIPEC is safe for advanced gastric cancer patients after treatment by radical resection and can effectively improve illness-specific 3-year disease-free survival.Keywords: gastric cancer, hyperthermic intraperitoneal chemotherapy, lobaplatin, safetyhttps://www.dovepress.com/lobaplatin-in-prophylactic-hyperthermic-intraperitoneal-chemotherapy-f-peer-reviewed-article-CMARgastric cancerhyperthermic intraperitoneal chemotherapylobaplatinsafety |
| spellingShingle | Zhong Y Zhang J Bai X Sun Y Liu H Ma S Li Y Kang W Ma F Li W Tian Y Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles Cancer Management and Research gastric cancer hyperthermic intraperitoneal chemotherapy lobaplatin safety |
| title | Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles |
| title_full | Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles |
| title_fullStr | Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles |
| title_full_unstemmed | Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles |
| title_short | Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles |
| title_sort | lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy for advanced gastric cancer safety and efficacy profiles |
| topic | gastric cancer hyperthermic intraperitoneal chemotherapy lobaplatin safety |
| url | https://www.dovepress.com/lobaplatin-in-prophylactic-hyperthermic-intraperitoneal-chemotherapy-f-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT zhongy lobaplatininprophylactichyperthermicintraperitonealchemotherapyforadvancedgastriccancersafetyandefficacyprofiles AT zhangj lobaplatininprophylactichyperthermicintraperitonealchemotherapyforadvancedgastriccancersafetyandefficacyprofiles AT baix lobaplatininprophylactichyperthermicintraperitonealchemotherapyforadvancedgastriccancersafetyandefficacyprofiles AT suny lobaplatininprophylactichyperthermicintraperitonealchemotherapyforadvancedgastriccancersafetyandefficacyprofiles AT liuh lobaplatininprophylactichyperthermicintraperitonealchemotherapyforadvancedgastriccancersafetyandefficacyprofiles AT mas lobaplatininprophylactichyperthermicintraperitonealchemotherapyforadvancedgastriccancersafetyandefficacyprofiles AT liy lobaplatininprophylactichyperthermicintraperitonealchemotherapyforadvancedgastriccancersafetyandefficacyprofiles AT kangw lobaplatininprophylactichyperthermicintraperitonealchemotherapyforadvancedgastriccancersafetyandefficacyprofiles AT maf lobaplatininprophylactichyperthermicintraperitonealchemotherapyforadvancedgastriccancersafetyandefficacyprofiles AT liw lobaplatininprophylactichyperthermicintraperitonealchemotherapyforadvancedgastriccancersafetyandefficacyprofiles AT tiany lobaplatininprophylactichyperthermicintraperitonealchemotherapyforadvancedgastriccancersafetyandefficacyprofiles |